Pharmaceuticals Search Engine [selected websites]


Tuesday, June 28, 2011

Adocia : positive phase I clinical results on HinsBet®, a fast-acting human insulin

AdociaLyon-France, March 15, 2011, Adocia, a privately-held biotechnology company specialized in
regenerative medicine and in the treatment of chronic diseases, announced positive
results from its phase I clinical study evaluating the safety and clinical utility of HinsBet®, its fast-acting human insulin product for the treatment of diabetes. This project benefits from FEDER support.
The trial compared the product candidate, HinsBet®, to NovoLog® (Novo Nordisk), a fast-acting insulin analog, and Actrapid® (Novo Nordisk), a regular human insulin. It was a double blind study involving 12 healthy volunteers. The pharmacokinetic and pharmacodynamic profiles were obtained using the glucose clamp technique.
On the primary endpoint of safety, HinsBet® showed identical results to the commercial products tested, giving excellent local tolerance and absence of pain at the site of injection...


...About Adocia SAS

Adocia (Lyon, France) is a privately held French biotechnology company in specialized regenerative medicine and in the treatment of chronic diseases. Adocia is developing innovative protein formulations based on its proprietary technology, BioChaperone®. These include new formulations of BMPs (bone morphogenic proteins) for bone repair and other indications. Adocia is also engaged in two collaborative programs on the formulation of monoclonal antibodies using its BioChaperone® platform with two biopharma companies, and it has three collaborations with medtech companies... [PDF] Adocia's Press Release -

Thursday, June 23, 2011

PathoQuest SAS, raises 2M€ with Kurma BioFund in its first round of financing

PathoQuestParis, 2011 the 29th of march - French pathogens discovery biotechnology start–up, PathoQuest SAS, raises 2M€ with Kurma BioFund in its first round of financing -
Founded in September 2010 by Professor Marc Eloit and Luc Boblet (PhD), PathoQuest SAS completed, on March 11th 2011, its first round of financing securing 2 M€ with the Kurma BioFund. A spin-off from the Pasteur Institute and the Ecole Nationale Vétérinaire d’Alfort (ENVA), PathoQuest has developed a proprietary expertise in metagenomics and pathogens identification by “Binning” or “De novo assembling” of high-throughput generated sequences.

By discovering the etiology of major pathologies, in the field of infectious diseases and oncology, PathoQuest is committed to providing valuable new targets for diagnosis and vaccines to majors companies...


...About PathoQuest

A spin-off from the Pasteur Institute and l’Ecole Nationale Vétérinaire d’Alfort (ENVA), PathoQuest is a biotechnology start-up company dedicated to identifying pathogens by means of High Throughput Sequencing (HTS). PathoQuests’ extensive range of R&D programs in the fields of infectious diseases and oncology - both in-house and in collaboration with academic/industrial partners, permits PathoQuest to discover the etiology of major pathologies. PathoQuest is committed to providing diagnosis and vaccine pharmaceutical companies with valuable new targets. PathoQuest ultimately aims to be a pioneer in HTS-based medical diagnosis.

Kurma BioFund
About Kurma Life Sciences Partners

Kurma Biofund is a venture capital fund managed by Paris based Kurma Life Sciences Partners (KLS Partners). Founded in July 2009, Kurma manages in excess of 135M€. KLS Partners is supported by two long-term investors (Natixis, part of Group BPCE the second largest French bank, and stateowned Caisse des Dépots et Consignations – CDC). Kurma actively invests in all stages of the biotech value chain, from technology transfer through to more established companies... [PDF] PathoQuest's Press Release - PDF du communiqué de presse de Kurma bioFund -

Friday, June 17, 2011

Cellectis and VitamFero Collaborate to Develop Vaccines against Parasitic Infection

VitamFeroParis and Evry (France), June 6, 2011 – Cellectis (Alternext: ALCLS), the genome engineering specialist, and VitamFero, a biotech company of the Genopole® portfolio developing new vaccines against parasite infections, announced the signing of a research, development and licensing partnership agreement. This agreement will grant VitamFero access to Cellectis’ proprietary meganuclease technology for the design and development of a new generation of living attenuated vaccines.

Under this 5-year agreement, Cellectis will supply VitamFero with preselected méganucléases for initial use in the development of vaccines against parasites responsible for toxoplasmosis, neosporosis, and others...


About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

About VitamFero

Created in 2005 and having just completed a significant raise of 1.1 M€, VitamFero exploits the breakthroughs jointly obtained and patented by CNRS, INRA and Université François Rabelais in Tours (France) in the domain of antiparasite vaccines, an area where needs are still largely unmet. VitamFero is built on a strong and validated scientific basis, based on the development of living parasite strains (i.e. Toxoplasma gondii, …), attenuated by complete and targeted deletion of virulence genes... [PDF] Cellectis' Press Release - PDF du communiqué de presse de VitamFero -

Tuesday, June 14, 2011

InnaVirVax : results showing the prognosis value of anti-3S antibodies

InnaVirVaxMarch 2011 - InnaVirVax and scientists from Inserm, University Pierre & Marie Curie (Paris) and University Paris-Sud (Paris), presented results showing the prognosis value of anti-3S antibodies at the International Workshop on HIV Observational Databases in Prague. (InnaVirVax's News)

About InnaVirVax

Mission Statment

InnaVirVax is a privately-owned biopharmaceutical company dedicated to the development of a cutting edge discovery in the field of therapy/prevention and prognostic of AIDS and HIV infection and new cancer therapies.

Company Mission

InnaVirVax is developing product candidates resulting from a breakthrough discovery. Based on a new paradigm (i.e. the understanding of the mechanism responsible for the decline of the CD4+ T lymphocytes in HIV-infected patients), the products currently developed by InnaVirVax will allow the prevention and the treatment of AIDS in HIV-infected patients. Moreover InnaVirVax has an AIDS prognostic test in its R&D portfolio.
Lastly, InnaVirVax is developing an innovative cancer biotherapy relying on a totally new tumor surface antigen.
InnaVirVax product portfolio originates from Inserm, the French Medical research council, the AP-HP, the largest hospital in Europe, and University Pierre et Marie Curie in Paris... InnaVirVax's mission -